Moderna 2022 Priorities and Capital Allocation
COVID booster development for endemic phase
Strategic rationale
for seasonal booster
Desired features for
the northern
hemisphere (NH)
Fall/Winter '22-23
booster
Slide 15
.
•
•
Neutralizing titers (NT) will wane, similar to endemic HCOV
Decline in NT will increase risk of breakthrough hospitalization for
those at higher risk (e.g., older adults, immune compromised)
Emergence of new variants of concern (VOC) could accelerate
the impact of waning and broaden risk of breakthrough
Improve durability of protective neutralizing antibodies against
Omicron to 6+ months (i.e., the full NH fall-winter infection season)
Retain high and durable protection against Delta and ancestral
strains
Broaden cross-protective immunity to increase potential for
protection against a new (emergent) VOC mid-year
modernaView entire presentation